Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications

AI Briefing

• – Junshi Biosciences receives NMPA approval for toripalimab injection in 12 indications.
• – NMPA approves NDA for toripalimab injection for various cancers and autoimmune diseases.
• – Junshi Biosciences' toripalimab injection gets regulatory green light from NMPA.